NCT04616560 2026-03-18Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent OsteosarcomaNational Cancer Institute (NCI)Phase 2 Suspended77 enrolled
NCT05372614 2026-03-18Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneNational Cancer Institute (NCI)Phase 1 Suspended33 enrolled